» Articles » PMID: 14622169

Markers for Dopaminergic Neurotransmission in the Cerebellum in Normal Individuals and Patients with Parkinson's Disease Examined by RT-PCR

Overview
Journal Eur J Neurosci
Specialty Neurology
Date 2003 Nov 19
PMID 14622169
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of neuronal elements that are indicative of dopaminergic neurotransmission in cerebellum suggest that this brain region may contribute to the motor symptoms or dyskinesia seen in Parkinson's disease. Reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of markers for dopaminergic neurotransmission in the cerebellum from postmortem brain tissue obtained from normal subjects and patients dying with Parkinson's disease who were receiving treatment with dopaminergic drugs. Dopamine D1-3 receptors, tyrosine hydroxylase and dopamine transporter mRNA was detected in the uvula and nodulus (lobules 9 and 10, respectively) of the vermis of cerebellum from normal individuals. In Parkinson's disease, the level of dopamine D1 and D3 receptor mRNA was significantly reduced in lobule 9 and the level of tyrosine hydroxylase mRNA was significantly reduced in lobule 10. No alteration in the level of dopamine D2 receptor or dopamine transporter mRNA was found in either lobule in patients with Parkinson's disease. These results show that mRNA expression for the functional components of dopaminergic neurotransmission is present in human cerebellum. The discrete changes in the levels of dopamine D1 and D3 receptors and tyrosine hydroxylase mRNA in cerebellum from l-DOPA treated Parkinson's disease patients suggests that this brain area has a role in the symptoms of Parkinson's disease and/or the beneficial/side-effects of treatment.

Citing Articles

Cerebellum in neurodegenerative diseases: Advances, challenges, and prospects.

Liu G, Yang C, Wang X, Chen X, Cai H, Le W iScience. 2024; 27(11):111194.

PMID: 39555407 PMC: 11567929. DOI: 10.1016/j.isci.2024.111194.


Cerebellum in Alzheimer's disease and other neurodegenerative diseases: an emerging research frontier.

Yang C, Liu G, Chen X, Le W MedComm (2020). 2024; 5(7):e638.

PMID: 39006764 PMC: 11245631. DOI: 10.1002/mco2.638.


Cerebellum and Aging: Update and Challenges.

McElroy C, Wang B, Zhang H, Jin K Aging Dis. 2024; 15(6):2345-2360.

PMID: 38502583 PMC: 11567260. DOI: 10.14336/AD.2024.0220.


Challenges and innovations in brain PET analysis of neurodegenerative disorders: a mini-review on partial volume effects, small brain region studies, and reference region selection.

Kanel P, Carli G, Vangel R, Roytman S, Bohnen N Front Neurosci. 2023; 17:1293847.

PMID: 38099203 PMC: 10720329. DOI: 10.3389/fnins.2023.1293847.


Linking the cerebellum to Parkinson disease: an update.

Li T, Le W, Jankovic J Nat Rev Neurol. 2023; 19(11):645-654.

PMID: 37752351 DOI: 10.1038/s41582-023-00874-3.